CTOs on the Move

The South Carolina Neurological Clinic, PA

www.scneuroclinic.com

 
The South Carolina Neurological Clinic, PA is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Gateway Health

Gateway Health is a nationally ranked managed care organization that focuses on providing the best possible healthcare to a growing number of Medicaid and Medicare Advantage consumers. A not-for-profit organization, Gateway Health serves the needs of at risk and vulnerable citizens with not only healthcare coverage, but services such as disease management, health and wellness programs and preventive care. The organization provides Medicaid services in Pennsylvania, Delaware, Arkansas and West Virginia and Medicare coverage in Pennsylvania, Kentucky, Ohio and North Carolina. Our commitment to helping our members and their communities get and stay healthy is what keeps members, providers, communities and partners Good with Gateway.

Cancer Expert Now

Cancer Expert Now`s services connect you to distinguished experts to discuss current disease challenges, recent literature, global clinical findings, and even share their research and experience in the context of your specific diagnosis, or patient cases.

Tango2

Tango2 is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jackson Park Christian Home

Jackson Park Christian Home is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Geron

We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.